Dear Aysan, 

Thank you for your kind email and invitation to the meeting scheduled for October 7 and 8 in Tashkent.

As you know our team is responsible for the implementation of clinical component of Georgia’s HCV elimination program. Accordingly, if you need a specialist/speaker from this field, we nominate a candidature of Dr. Lali Sharvadze, who is a leading specialist from Infectious Diseases and AIDS center as well as from hepatology clinic ‘HEPA’. Together with me Dr. Sharvadze has been responsible for all clinical activities (clinical guidelines/protocols, clinical management of patients, training of physicians etc.) within the elimination program.

Thank you in advance for your kind consideration and look forward to hearing from you.

Best regards,

Tengiz Tsertsvadze

Dear Dr Tengiz and Dr Amiran

I hope you are all doing well.

As you might heard Uzbekistan has also started to work on an HCV elimination project and they need guidance. My colleague Ben (responsible for EECA region) and I thought it will be good to bring doctors from Egypt, Mongolia and Georgia to Tashkent to share their experiences on screening, linkage to care, decentralisation etc etc. The meeting will be held on October 7 and 8 in Tashkent.

We would like to invite one speaker from Georgia to Uzbekistan Viral Hepatitis Stakeholder Meeting depending on availability during those days and willingness to be part of the faculty. I thought it’s better to get your opinion as you are leading the two institute.

Looking forward to hearing from you

Best

Aysan

 

 

AYSAN MURTEZAOĞLU | Senior Director, Public Health & Medical Affairs, Access Operations & Emerging Markets |

 Gilead Sciences İlaç. Tic. Ltd. Şti | AND Plaza, İçerenköy Mah. Umut Sok. No: 10/12 Kat:21 | Ataşehir, İstanbul TR 34752

Tel: +90 216 559 0300 | Gsm: +90 532 373 39 32

 

…………………………………………………………………………………………………………………………………………………………………

                                                                            DISCLAIMER
 If you have received this message in error, please contact the sender immediately by return e-mail and notify the sender and then delete
this message (including any attachments) from your system. This communication and any attachments contain information which is confidential
and may also be legally privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s) please note that
any form of disclosure, distribution, copying or use of this communication or the information in it or in any attachments is strictly prohibited and
may be unlawful.
E-mail communications cannot be guaranteed to be secure or error free, as information could be intercepted, corrupted, amended, lost, destroyed,
arrive late or incomplete or contain viruses. Gilead does not accept liability for any such matters or their consequences. Anyone who communicates
with Gilead by e-mail is taken to accept the risks in doing so. Gilead has taken every reasonable precaution to ensure that any attachment to this
e-mail has been swept for viruses. However Gilead cannot accept liability for any damage sustained as a result of viruses and would advise that
you carry out your own virus checks before opening any attachment.

P   Please consider the environment before printing this e-mail.

 

If you have received this message in error, please contact the sender immediately by return e-mail and notify the sender and then delete this message (including any attachments) from your system. This communication and any attachments contain information which is confidential and may also be legally privileged. It is for the exclusive use of the intended recipient(s). If you are not the intended recipient(s) please note that any form of disclosure, distribution, copying or use of this communication or the information in it or in any attachments is strictly prohibited and may be unlawful. If your e-mail contains any personal information then we will process this according to our Privacy Statement located on Gilead.com. E-mail communications cannot be guaranteed to be secure or error free, as information could be intercepted, corrupted, amended, lost, destroyed, arrive late or incomplete, or contain viruses. Gilead does not accept liability for any such matters or their consequences. Anyone who communicates with Gilead by e-mail is taken to accept the risks in doing so. Gilead has taken every reasonable precaution to ensure that any attachment to this e-mail has been swept for viruses. However, Gilead cannot accept liability for any damage sustained as a result of viruses and would advise that you carry out your own virus checks before opening any attachment.